Trial · NCT00859222
Participant flow15
How many started, completed or left each group, period by period.
1 to 15 of 15
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase I Cohort 1: Bevacizumab +LBH589 20 mg Every Week | 3 | |
| Overall Study | STARTED | Phase I Cohort 2: Bevacizumab + LBH589 20 mg Every Other Week | 3 | |
| Overall Study | STARTED | Phase I Cohort 3: Bevacizumab + LBH589 30 mg Every Other Week | 6 | |
| Overall Study | STARTED | Phase II GBM: Bevacizumab + LBH589 30 mg Every Other Week | 24 | |
| Overall Study | STARTED | Phase II AG: Bevacizumab + LBH589 30 mg Every Other Week | 15 | |
| Overall Study | COMPLETED | Phase I Cohort 1: Bevacizumab +LBH589 20 mg Every Week | 0 | |
| Overall Study | COMPLETED | Phase I Cohort 2: Bevacizumab + LBH589 20 mg Every Other Week | 0 | |
| Overall Study | COMPLETED | Phase I Cohort 3: Bevacizumab + LBH589 30 mg Every Other Week | 0 | |
| Overall Study | COMPLETED | Phase II GBM: Bevacizumab + LBH589 30 mg Every Other Week | 0 | |
| Overall Study | COMPLETED | Phase II AG: Bevacizumab + LBH589 30 mg Every Other Week | 0 | |
| Overall Study | NOT COMPLETED | Phase I Cohort 1: Bevacizumab +LBH589 20 mg Every Week | 3 | |
| Overall Study | NOT COMPLETED | Phase I Cohort 2: Bevacizumab + LBH589 20 mg Every Other Week | 3 | |
| Overall Study | NOT COMPLETED | Phase I Cohort 3: Bevacizumab + LBH589 30 mg Every Other Week | 6 | |
| Overall Study | NOT COMPLETED | Phase II GBM: Bevacizumab + LBH589 30 mg Every Other Week | 24 | |
| Overall Study | NOT COMPLETED | Phase II AG: Bevacizumab + LBH589 30 mg Every Other Week | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00859222/flow